What is the initial evaluation and management approach for a patient presenting with hematuria (blood in urine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differential Diagnosis of Hematuria

Primary Classification

Hematuria must first be classified as either gross (visible) or microscopic, as this fundamentally determines malignancy risk and urgency of evaluation. Gross hematuria carries a 30-40% malignancy risk, while microscopic hematuria has only a 2.6-4% risk 1.

Gross Hematuria Etiologies

  • Malignancy (30-40% of cases): Bladder cancer (most common), renal cell carcinoma, upper tract urothelial carcinoma 1
  • Urolithiasis: Kidney or ureteral stones causing mucosal trauma 1
  • Infection: Severe cystitis, pyelonephritis, prostatitis 1
  • Trauma: Blunt or penetrating renal injury, bladder injury with pelvic fractures 1
  • Benign prostatic hyperplasia: Particularly in older men 1
  • Coagulopathy or anticoagulation: Though this alone does NOT explain hematuria and requires full evaluation 1

Microscopic Hematuria Etiologies

Non-Glomerular (Urologic) Causes

  • Malignancy: Bladder cancer, renal cell carcinoma, upper tract urothelial carcinoma (lower risk than gross hematuria) 1
  • Urolithiasis: Small stones causing microscopic bleeding 1
  • Infection: Urinary tract infection, prostatitis 1
  • Benign prostatic hyperplasia: Common in men over 40 1
  • Anatomic abnormalities: Polycystic kidney disease, medullary sponge kidney 1

Glomerular (Nephrologic) Causes

  • IgA nephropathy: Most common cause of isolated glomerular hematuria 2
  • Thin basement membrane disease (benign familial hematuria) 2
  • Alport syndrome: Hereditary nephritis with hearing loss 2
  • Post-infectious glomerulonephritis: Following streptococcal infection 3
  • Lupus nephritis, vasculitis, other systemic diseases 3

Risk Stratification for Malignancy

The 2025 AUA/SUFU guideline provides a critical risk stratification system that determines evaluation intensity 1:

High Risk (1.3-6.3% malignancy risk)

  • Men ≥60 years 1
  • >25 RBC/HPF on urinalysis 1
  • Smoking history >30 pack-years 1
  • History of gross hematuria with 3-25 RBC/HPF on repeat urinalysis 1

Intermediate Risk (0.2-3.1% malignancy risk)

  • Men 40-59 years or women ≥60 years 1
  • 11-25 RBC/HPF 1
  • Smoking history 10-30 pack-years 1

Low/Negligible Risk (0-0.4% malignancy risk)

  • Men <40 years and women <60 years 1
  • 3-10 RBC/HPF 1
  • Never smoker or <10 pack-years 1

Distinguishing Glomerular from Non-Glomerular Sources

Features Suggesting Glomerular Origin

  • Dysmorphic RBCs (>80% of RBCs) on phase-contrast microscopy 2, 3
  • Red blood cell casts (pathognomonic for glomerular disease) 2
  • Significant proteinuria (>300 mg/day or protein/creatinine ratio >0.3) 2
  • Elevated serum creatinine suggesting renal parenchymal disease 1, 2
  • Hypertension in the absence of other causes 2

Features Suggesting Non-Glomerular Origin

  • Normal-shaped (isomorphic) RBCs 2
  • Minimal or no proteinuria 2
  • Normal serum creatinine 2
  • Presence of clots (glomerular bleeding does not clot) 4

Additional Differential Considerations

Benign Transient Causes (Exclude Before Extensive Workup)

  • Vigorous exercise: Resolves within 48-72 hours of rest 1
  • Menstruation: Ensure proper specimen collection 1
  • Sexual intercourse: Recent trauma 1
  • Viral illness: Transient glomerular inflammation 3

Medication-Induced Hematuria

  • Cyclophosphamide: Hemorrhagic cystitis 3
  • Anticoagulants/antiplatelets: Do NOT explain hematuria; full evaluation still required 1
  • NSAIDs: Analgesic nephropathy, papillary necrosis 3

Occupational/Environmental Exposures

  • Aromatic amines, benzene chemicals: Dye, rubber, leather industries (bladder cancer risk) 1
  • Aristolochic acid: Herbal supplements (upper tract urothelial carcinoma) 1

Critical Pitfalls to Avoid

  • Never attribute hematuria solely to anticoagulation or antiplatelet therapy without complete evaluation 1
  • Do not delay urologic referral for gross hematuria even if bleeding resolves spontaneously 2, 5
  • Do not use urine cytology or molecular markers (NMP22, BTA stat) in initial evaluation of asymptomatic microscopic hematuria 1
  • Recognize that significant renal injuries can occur with microscopic hematuria in trauma patients; mechanism of injury matters more than degree of hematuria 1
  • Isolated microscopic hematuria in children without trauma, infection, or concerning features rarely requires imaging 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Evaluation of Hematuria in the Elderly

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Approach to Diagnosis and Management of Hematuria.

Indian journal of pediatrics, 2020

Research

Macroscopic haematuria--a urological approach.

Australian family physician, 2013

Research

Hematuria.

Primary care, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.